HK1183678A1 - Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules (hla)ii - Google Patents

Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules (hla)ii

Info

Publication number
HK1183678A1
HK1183678A1 HK13111197.3A HK13111197A HK1183678A1 HK 1183678 A1 HK1183678 A1 HK 1183678A1 HK 13111197 A HK13111197 A HK 13111197A HK 1183678 A1 HK1183678 A1 HK 1183678A1
Authority
HK
Hong Kong
Prior art keywords
hla
molecules
tumour
present
relates
Prior art date
Application number
HK13111197.3A
Other languages
English (en)
Chinese (zh)
Inventor
約恩．登扎爾
Original Assignee
伊瑪提克斯生物技術有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 伊瑪提克斯生物技術有限公司 filed Critical 伊瑪提克斯生物技術有限公司
Publication of HK1183678A1 publication Critical patent/HK1183678A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK13111197.3A 2005-09-05 2013-10-02 Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules (hla)ii HK1183678A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05019254A EP1760088B1 (en) 2005-09-05 2005-09-05 Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules

Publications (1)

Publication Number Publication Date
HK1183678A1 true HK1183678A1 (en) 2014-01-03

Family

ID=35170099

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13111197.3A HK1183678A1 (en) 2005-09-05 2013-10-02 Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules (hla)ii
HK16108913.9A HK1220709A1 (zh) 2005-09-05 2016-07-26 混雜地結合於人類白細胞抗原 類分子的腫瘤相關肽

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16108913.9A HK1220709A1 (zh) 2005-09-05 2016-07-26 混雜地結合於人類白細胞抗原 類分子的腫瘤相關肽

Country Status (23)

Country Link
US (6) US10196432B2 (xx)
EP (6) EP1806359B1 (xx)
JP (1) JP5627180B2 (xx)
KR (3) KR101386355B1 (xx)
CN (3) CN103059104B (xx)
AT (5) ATE388164T1 (xx)
AU (2) AU2006289290B2 (xx)
BR (1) BRPI0615462A2 (xx)
CA (2) CA2621389C (xx)
CY (5) CY1107973T1 (xx)
DE (4) DE602005020046D1 (xx)
DK (5) DK1806358T3 (xx)
EA (1) EA013876B1 (xx)
ES (5) ES2302546T3 (xx)
HK (2) HK1183678A1 (xx)
HR (2) HRP20100128T1 (xx)
NO (1) NO340870B1 (xx)
NZ (2) NZ588813A (xx)
PL (5) PL1760088T3 (xx)
PT (5) PT1806359E (xx)
SI (5) SI1806359T1 (xx)
UA (1) UA98295C2 (xx)
WO (1) WO2007028574A2 (xx)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1806359B1 (en) * 2005-09-05 2010-03-17 Immatics Biotechnologies GmbH Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
EP2562182B1 (en) 2007-07-27 2015-10-07 Immatics Biotechnologies GmbH Novel immunogenic epitopes for immunotherapy
SI2660248T1 (sl) 2007-07-27 2015-10-30 Immatics Biotechnologies Gmbh Nova imunoterapija proti možganskim tumorjem
CN101765434B (zh) 2007-07-27 2014-12-17 伊玛提克斯生物技术有限公司 抗肿瘤相关肽及相关抗癌疫苗组合物
ES2632123T3 (es) 2007-08-20 2017-09-11 Oncotherapy Science, Inc. Péptido CDH3 y agente medicinal que comprende el mismo
CN102066410B (zh) 2007-11-01 2017-01-18 梅约医学教育与研究基金会 Hla‑dr结合肽和它们的应用
SI2105501T1 (sl) 2008-03-27 2015-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija proti nevronalnim in možganskim tumorjem
SI2113253T1 (sl) * 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
DK2119726T5 (en) 2008-05-14 2018-03-26 Immatics Biotechnologies Gmbh Novel and powerful MHC class II peptides derived from survivin and neurocan
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
RS53782B1 (en) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh TUMOR-ASSOCIATED PEPTIDES PREPARED AND ANTI-CHANGE RESPONSE FOR GLIOBLASTOMA (GBM) AND OTHER CANCER TREATMENTS
PL2623517T3 (pl) 2009-01-28 2016-04-29 Ind Tech Res Inst Biomarkery w moczu i surowicy związane z nefropatią cukrzycową
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
MX2013006758A (es) 2010-12-14 2013-08-01 Immatics Biotechnologies Gmbh Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos.
CN103502438A (zh) * 2011-03-23 2014-01-08 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
TWI777195B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（三）
HRP20211852T1 (hr) 2013-08-05 2022-03-18 Immatics Biotechnologies Gmbh Nova imunoterapija protiv nekoliko tumora, poput raka pluća, uključujući nsclc
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
IL248203A0 (en) 2014-05-09 2016-11-30 Immatics Biotechnologies Gmbh Innovative immunotherapy against blood tumors such as acute leukemia in the spinal cord
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
MA49157A (fr) 2014-12-23 2021-06-02 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
IL254129B2 (en) 2015-03-27 2023-10-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PE20230321A1 (es) 2015-07-01 2023-02-22 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
KR20180026758A (ko) 2015-07-06 2018-03-13 이매틱스 바이오테크놀로지스 게엠베하 식도암 및 기타 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
GB201512369D0 (en) 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
TWI796642B (zh) 2015-08-28 2023-03-21 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
MY198087A (en) 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
IL298653A (en) 2015-12-11 2023-01-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides for use in immunotherapy against several types of cancer
IL259931B2 (en) 2015-12-16 2024-02-01 Gritstone Bio Inc Identification of neo-antigens, preparation, and use
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
MA54832A (fr) 2016-03-01 2021-12-01 Immatics Biotechnologies Gmbh Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
US20190307868A1 (en) * 2016-03-31 2019-10-10 Neon Therapeutics, Inc. Neoantigens and methods of their use
MY197258A (en) 2016-04-06 2023-06-08 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
CA3021159A1 (en) 2016-04-21 2017-10-26 Immatics Biotechnologies Gmbh Immunotherapy against melanoma and other cancers
JP2019520038A (ja) 2016-04-21 2019-07-18 イマティクス バイオテクノロジーズ ゲーエムベーハー 黒色腫およびその他のがんに対する免疫療法
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
CA3027124A1 (en) * 2016-06-10 2017-12-14 Umc Utrecht Holding B.V. Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response
TW202304970A (zh) * 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
IL299051A (en) 2017-01-27 2023-02-01 Immatics Biotechnologies Gmbh New peptides and their combinations for immunotherapy against ovarian cancer and other cancers
AR110857A1 (es) 2017-01-27 2019-05-08 Immatics Biotechnologies Gmbh Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
MA47367B1 (fr) 2017-01-27 2023-06-28 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
WO2018145048A1 (en) * 2017-02-06 2018-08-09 Academia Sinica Recombinant proteins and uses thereof
SG11201909058WA (en) 2017-04-10 2019-10-30 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
WO2018189152A2 (en) 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
WO2018189148A1 (en) 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
CN111548405A (zh) * 2017-04-10 2020-08-18 伊玛提克斯生物技术有限公司 用于癌症免疫治疗的肽及其肽组合物
WO2019007974A1 (en) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
CR20210168A (es) 2017-07-07 2021-06-10 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres
MX2020002891A (es) 2017-09-18 2021-01-08 S & P Ingredient Dev Llc Sustituto de sal bajo en sodio con cloruro de potasio.
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
CA3090416A1 (en) 2018-02-09 2019-08-15 Immatics US, Inc. Methods for manufacturing t cells
DE102018108996B4 (de) 2018-02-09 2021-10-21 Immatics US, Inc. Verfahren zur Herstellung autologer T-Zellen
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
AU2019227813B2 (en) * 2018-02-27 2024-06-27 Gritstone Bio, Inc. Neoantigen identification with pan-allele models
EP3539562A1 (en) * 2018-03-12 2019-09-18 Eberhard Karls Universität Tübingen Medizinische Fakultät Immunotherapeutic peptides
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
KR102215578B1 (ko) * 2019-03-28 2021-02-15 한국과학기술연구원 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도
CA3142386A1 (en) 2019-06-06 2020-12-10 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
CN110305209B (zh) * 2019-07-09 2022-09-13 福建医科大学附属第一医院 用于治疗恶性肿瘤的多肽及其作为疫苗的用途
BR112022001688A2 (pt) * 2019-07-30 2022-05-24 Univ Health Network Receptores de células t e métodos de uso dos mesmos
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
US11891427B2 (en) 2020-09-29 2024-02-06 Immatics Biotechnologies Gmbh Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof
CN117720620B (zh) * 2023-12-13 2024-07-23 无锡市儿童医院 小分子多肽和其药物组合物、其制药用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211999B2 (en) * 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8258260B2 (en) * 1970-02-11 2012-09-04 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8212000B2 (en) * 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
GR66050B (xx) * 1977-09-20 1981-01-14 Licinvest Ag
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IN151589B (xx) 1978-12-22 1983-05-28 Biogen Nv
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4810781A (en) * 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens
JPH07508403A (ja) * 1992-04-03 1995-09-21 ラ　ホヤ　キャンサー　リサーチ　ファウンデーション デコリンフラグメントおよび細胞調節因子を阻害する方法
CA2142007C (en) * 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
WO1995011923A1 (en) * 1993-10-29 1995-05-04 Dana-Farber Cancer Institute, Inc. A novel tumor marker and novel method of isolating same
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2195642A1 (en) 1994-07-27 1996-02-08 Andreas Suhrbier Polyepitope vaccines
UY24367A1 (es) * 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
ATE244300T1 (de) 1996-01-17 2003-07-15 Imp College Innovations Ltd Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
US6610821B1 (en) * 1996-07-12 2003-08-26 Mcgill University Compounds and methods for modulating endothelial cell adhesion
AU6241698A (en) * 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Tace-like and matrilysin-like polypeptides
US6316213B1 (en) * 1997-03-19 2001-11-13 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian, breast and lung cancer
EP1023445B1 (de) * 1997-10-15 2005-08-17 Pharis Biotec GmbH Cadherin derived growth factor und seine verwendung
DE19757250A1 (de) * 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
US6746852B1 (en) * 1998-05-08 2004-06-08 Osi Pharmaceuticals, Inc. AGS proteins and nucleic acid molecules and uses thereof
DE19936563A1 (de) 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumorassoziiertes Antigen
DE19938583A1 (de) 1999-08-18 2001-02-22 Buehler Ag Verfahren und Vorrichtung zur Herstellung von kristallisationsfähigem Kunststoffmaterial
WO2001057252A2 (en) * 2000-02-04 2001-08-09 Aeomica, Inc. Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
AU2001277172A1 (en) * 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-trans protein and related reagents and methods of use thereof
WO2002050103A2 (en) 2000-12-20 2002-06-27 Glaxosmithkline Biologicals S.A. Tumour-related antigens
WO2002078516A2 (en) 2001-03-30 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7049413B2 (en) * 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US7705120B2 (en) * 2001-06-21 2010-04-27 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
ATE403149T1 (de) * 2001-08-13 2008-08-15 Dana Farber Cancer Inst Inc Diagnostische tests auf periostinbasis
US6906036B2 (en) * 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
AU2002335824A1 (en) * 2001-10-12 2003-04-22 Case Western Reserve University Neuronal regeneration
WO2003068940A2 (en) * 2002-02-14 2003-08-21 Curagen Corporation Complexes and methods of using same
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
AU2002368151A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Matrix metalloproteinase inhibitors and methods for identification of lead compounds
AU2003295328A1 (en) * 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2006515318A (ja) * 2002-10-29 2006-05-25 ファルマシア・コーポレーション 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
JP2007504842A (ja) * 2003-05-29 2007-03-08 ミレニアム ファーマシューティカルズ， インコーポレイテッド 乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法
EP1646648A2 (en) * 2003-07-15 2006-04-19 Genova Ltd. Secreted polypeptide species reduced in cardiovascular disorders
EP1757940A1 (en) 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
ATE440107T1 (de) * 2005-09-05 2009-09-15 Immatics Biotechnologies Gmbh Tumorassoziierte peptide, die hla klasse i oder ii-moleküle binden, und anti-tumor impfstoffe
EP1806359B1 (en) * 2005-09-05 2010-03-17 Immatics Biotechnologies GmbH Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
EP1795599A1 (en) * 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells

Also Published As

Publication number Publication date
US20080206216A1 (en) 2008-08-28
DK1806359T3 (da) 2010-06-14
EP1806359B1 (en) 2010-03-17
UA98295C2 (ru) 2012-05-10
AU2006289290B2 (en) 2010-11-25
US7807642B2 (en) 2010-10-05
ATE461215T1 (de) 2010-04-15
ES2341295T3 (es) 2010-06-17
DE602005020047D1 (de) 2010-04-29
DK2135878T3 (da) 2012-02-27
EP1806359A1 (en) 2007-07-11
PT2135878E (pt) 2012-01-05
ES2302546T3 (es) 2008-07-16
CN103059104A (zh) 2013-04-24
KR20130019033A (ko) 2013-02-25
EA200800677A1 (ru) 2008-08-29
EP1806358A2 (en) 2007-07-11
EP1806358A3 (en) 2007-10-03
ES2337399T3 (es) 2010-04-23
KR101386790B1 (ko) 2014-04-21
EP2138509A1 (en) 2009-12-30
JP5627180B2 (ja) 2014-11-19
KR20080052643A (ko) 2008-06-11
US20100040590A1 (en) 2010-02-18
EA013876B1 (ru) 2010-08-30
US7833969B2 (en) 2010-11-16
CY1110187T1 (el) 2015-01-14
EP1760088A1 (en) 2007-03-07
DE602005005196D1 (de) 2008-04-17
HRP20110981T1 (hr) 2012-02-29
AU2010236029A1 (en) 2010-11-18
CY1110051T1 (el) 2015-01-14
ATE388164T1 (de) 2008-03-15
SI1922335T1 (sl) 2010-04-30
PL1806358T3 (pl) 2010-08-31
KR20130019034A (ko) 2013-02-25
PL1922335T3 (pl) 2010-05-31
CA2929252A1 (en) 2007-03-15
CY1109849T1 (el) 2014-09-10
WO2007028574A2 (en) 2007-03-15
ATE461214T1 (de) 2010-04-15
ATE532795T1 (de) 2011-11-15
CY1107973T1 (el) 2013-09-04
PL2135878T3 (pl) 2012-06-29
DK1922335T3 (da) 2010-04-19
US20160115212A1 (en) 2016-04-28
CA2621389C (en) 2016-07-19
PL1760088T3 (pl) 2008-10-31
PL1806359T3 (pl) 2010-08-31
SI2135878T1 (sl) 2012-03-30
CN103059104B (zh) 2015-10-28
WO2007028574A9 (en) 2008-05-02
SI1760088T1 (sl) 2008-06-30
CA2621389A1 (en) 2007-03-15
EP1922335A2 (en) 2008-05-21
AU2010236029B2 (en) 2012-06-28
NZ566104A (en) 2011-04-29
NO340870B1 (no) 2017-07-03
PT1922335E (pt) 2010-03-03
KR101386355B1 (ko) 2014-04-17
DE602005005196T2 (de) 2008-06-26
AU2006289290A1 (en) 2007-03-15
NO20081683L (no) 2008-04-04
EP2135878B1 (en) 2011-11-09
ES2373907T3 (es) 2012-02-10
US10196432B2 (en) 2019-02-05
NZ588813A (en) 2011-06-30
HRP20100128T1 (hr) 2010-04-30
EP1760088B1 (en) 2008-03-05
JP2010502173A (ja) 2010-01-28
US20080206217A1 (en) 2008-08-28
EP1922335B1 (en) 2009-12-09
DK1806358T3 (da) 2010-06-28
US20080207520A1 (en) 2008-08-28
WO2007028574A3 (en) 2007-05-24
DE602005020046D1 (de) 2010-04-29
BRPI0615462A2 (pt) 2011-05-17
CN105440119A (zh) 2016-03-30
US10618945B2 (en) 2020-04-14
CN101287754B (zh) 2013-02-13
US7833970B2 (en) 2010-11-16
DK1760088T3 (da) 2008-06-09
ES2341802T3 (es) 2010-06-28
EP1806358B1 (en) 2010-03-17
SI1806359T1 (sl) 2010-06-30
EP2135878A1 (en) 2009-12-23
PT1806359E (pt) 2010-05-25
KR101386827B1 (ko) 2014-04-17
PT1760088E (pt) 2008-05-14
DE602006011030D1 (de) 2010-01-21
CN101287754A (zh) 2008-10-15
HK1220709A1 (zh) 2017-05-12
SI1806358T1 (sl) 2010-06-30
PT1806358E (pt) 2010-05-28
ATE451388T1 (de) 2009-12-15
CY1112186T1 (el) 2015-12-09
US20080206218A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
HK1220709A1 (zh) 混雜地結合於人類白細胞抗原 類分子的腫瘤相關肽
HRP20110240T1 (en) Tumor-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine
SI1794190T1 (sl) Imunogeni T-pomagalni epitopi iz humanih tumornih antigenov in imunoterapevtski postopki, ki uporabljajo navedene epitope

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190911